Cargando…

The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(−/−) mice by blocking monocyte/macrophage activation

OBJECTIVE: The incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide) are secreted by the gut after food intake leading to pancreatic insulin secretion and glucose lowering. Beyond its role in glucose control, GLP-1 was found in mice and men to beneficia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kahles, Florian, Liberman, Ana, Halim, Constantin, Rau, Matthias, Möllmann, Julia, Mertens, Robert Werner, Rückbeil, Marcia, Diepolder, Irmgard, Walla, Benedikt, Diebold, Sebastian, Burgmaier, Mathias, Lebherz, Corinna, Marx, Nikolaus, Lehrke, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034034/ https://www.ncbi.nlm.nih.gov/pubmed/29884547 http://dx.doi.org/10.1016/j.molmet.2018.05.014

Ejemplares similares

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction
por: Haj-Yehia, Elias, et al.
Publicado: (2020)

Association of Glucose‐Dependent Insulinotropic Polypeptide Levels With Cardiovascular Mortality in Patients With Acute Myocardial Infarction
por: Kahles, Florian, et al.
Publicado: (2021)

Interleukin-6 predicts inflammation-induced increase of Glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism
por: Lebherz, Corinna, et al.
Publicado: (2016)

The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
por: Ahrén, Bo, et al.
Publicado: (2019)

Co-localization of plaque macrophages with calcification is associated with a more vulnerable plaque phenotype and a greater calcification burden in coronary target segments as determined by OCT
por: Burgmaier, Mathias, et al.
Publicado: (2018)

Coronary plaque composition influences biomechanical stress and predicts plaque rupture in a morpho-mechanic OCT analysis
por: Milzi, Andrea, et al.
Publicado: (2021)

High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms
por: Schuett, Katharina Andrea, et al.
Publicado: (2015)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Prognostic irrelevance of plaque vulnerability following plaque sealing in high-risk patients with type 2 diabetes: an optical coherence tomography study
por: Dettori, Rosalia, et al.
Publicado: (2020)

Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes
por: Liberman, Ana, et al.
Publicado: (2013)

Correction: Glucagon-Like Peptide-1(9-36) Inhibits Chemokine-Induced Migration of Human CD4-Positive Lymphocytes
por: Liberman, Ana, et al.
Publicado: (2013)

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
por: El, K., et al.
Publicado: (2021)

Plaque vulnerability of coronary artery lesions is related to left ventricular dilatation as determined by optical coherence tomography and cardiac magnetic resonance imaging in patients with type 2 diabetes
por: Burgmaier, Mathias, et al.
Publicado: (2013)

A score to quantify coronary plaque vulnerability in high-risk patients with type 2 diabetes: an optical coherence tomography study
por: Burgmaier, Mathias, et al.
Publicado: (2014)

Investigation of endothelial nitric oxide (NO) signalling in response to the incretin hormone glucose-dependent insulinotropic polypeptide (GIP)
por: Savage, PJ, et al.
Publicado: (2012)

ADGRL3 genomic variation implicated in neurogenesis and ADHD links functional effects to the incretin polypeptide GIP
por: Vidal, Oscar M., et al.
Publicado: (2022)

Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study
por: Rau, Matthias, et al.
Publicado: (2022)

Gut immune cells—A novel therapeutical target for cardiovascular disease?
por: Ganesh, Naresh, et al.
Publicado: (2022)

Intrinsic calcification angle: a novel feature of the vulnerable coronary plaque in patients with type 2 diabetes: an optical coherence tomography study
por: Reith, Sebastian, et al.
Publicado: (2019)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

Annexin A5 reduces early plaque formation in ApoE -/- mice
por: Stöhr, Robert, et al.
Publicado: (2017)

Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy
por: Moffett, R. Charlotte, et al.
Publicado: (2014)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Rare Case of an Adult With Double-Chambered Left Ventricle
por: Frick, Michael, et al.
Publicado: (2022)

The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury
por: Kahles, Florian, et al.
Publicado: (2022)

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
por: Rau, Matthias, et al.
Publicado: (2021)

Low Adiponectin Levels Are an Independent Predictor of Mixed and Non-Calcified Coronary Atherosclerotic Plaques
por: Broedl, Uli C., et al.
Publicado: (2009)

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
por: Thiele, Kirsten, et al.
Publicado: (2022)

AnxA5 reduces plaque inflammation of advanced atherosclerotic lesions in apoE(−/−) mice
por: Burgmaier, Mathias, et al.
Publicado: (2014)

GIP1 and GIP2 Contribute to the Maintenance of Genome Stability at the Nuclear Periphery
por: Singh, Gaurav, et al.
Publicado: (2022)

Macroalgal protein hydrolysates from Palmaria palmata influence the ‘incretin effect’ in vitro via DPP-4 inhibition and upregulation of insulin, GLP-1 and GIP secretion
por: McLaughlin, C. M., et al.
Publicado: (2021)

Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study
por: Milzi, Andrea, et al.
Publicado: (2017)

Quantitative Flow Ratio Is Related to Intraluminal Coronary Stenosis Parameters as Assessed with Optical Coherence Tomography
por: Milzi, Andrea, et al.
Publicado: (2021)

Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
por: Ying, Zhixiong, et al.
Publicado: (2023)

Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects
por: Mizejewski, Gerald J.
Publicado: (2011)

The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
por: Schuett, Katharina, et al.
Publicado: (2023)

High cardiovascular risk of patients with type 2 diabetes is only partially attributed to angiographic burden of atherosclerosis
por: Battermann, Simone, et al.
Publicado: (2020)

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans
por: Piotrowski, Katja, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5bkn18asv2k8m2rk37ppdj8bmq